Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2023-08-25 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to first half interim 2023 results presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'PCI Biotech: Invitation to first half interim 2023 results presentation' and explicitly states that the company invites stakeholders to a webcast presentation of its 'first half 2023 interim report'. It also mentions that the interim report and presentation will be made available on the same day. Since the document is short (3118 chars) and its primary function is to announce the upcoming presentation and the availability of the interim report, it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The key phrase is 'Invitation to... presentation' and the announcement of when the report will be available.
2023-08-25 English
Minutes from Annual General Meeting 2023
AGM Information Classification · 99% confidence The document text is titled "PROTOKOLL FRA ORDINÆR GENERALFORSAMLING" which translates to "MINUTES FROM ORDINARY GENERAL MEETING". The content details the proceedings, resolutions passed (including approval of the 2022 annual accounts and election of the board), and attendees of a meeting held on May 25, 2023. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2023-05-25 Norwegian
Minutes from Annual General Meeting 2023
AGM Information Classification · 98% confidence The document is titled 'Minutes from Annual General Meeting 2023' and explicitly states that the minutes of the Annual General Meeting are 'attached to this release'. Given the very short length (654 characters) and the nature of the content (announcing the conclusion of the AGM and attaching the minutes), this fits the definition of a Report Publication Announcement (RPA) rather than the full minutes document itself (which would likely be classified as AGM-R if it were the presentation/material, or potentially LTR/RNS if it were a formal legal filing of the minutes). Since it is an announcement about the publication/attachment of the minutes, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2023-05-25 English
Disclosure of voting rights for Chairman of the Board
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly discusses the voting rights and share representation of the Chairman of the Board, Hans Peter Bøhn, specifically in the context of an upcoming Annual General Meeting (AGM) scheduled for May 25, 2023. It details his direct shareholding and the shares he represents via powers of attorney for that specific meeting. This content directly relates to the voting structure and representation at a general meeting, which aligns most closely with 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it is a pre-meeting disclosure of voting power, or potentially AGM Information (AGM-R) due to the direct link to the AGM agenda. Since it is a disclosure of voting rights *for* the meeting, DVA is the most precise fit, as it concerns the mechanics of voting rights.
2023-05-24 English
PCI Biotech interim Q1 2023 results
Investor Presentation Classification · 95% confidence The document is titled 'PCI Biotech - Q1 2023 Interim Report' and is explicitly labeled as a presentation. It contains operational reviews, key financial figures (tables for Q1 2023, Q1 2022, and FY 2022), and strategic outlooks. While it contains financial data, the format is a slide deck presentation used to communicate these results to investors, which aligns with the definition of an Investor Presentation (IP). Q1 2023
2023-05-12 English
PCI Biotech interim Q1 2023 results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for PCI Biotech for Q1 2023. It includes detailed financial statements (Income Statement, Balance Sheet), operational reviews, management commentary, and notes to the financial information. It is clearly an interim report rather than an announcement or a summary, as it contains substantive financial data and analysis for the specified period. Q1 2023
2023-05-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.